CA2503172A1 - Benzoxazocines et utilisation de ceux-ci comme inhibiteurs de la recapture des mono-amines - Google Patents

Benzoxazocines et utilisation de ceux-ci comme inhibiteurs de la recapture des mono-amines Download PDF

Info

Publication number
CA2503172A1
CA2503172A1 CA002503172A CA2503172A CA2503172A1 CA 2503172 A1 CA2503172 A1 CA 2503172A1 CA 002503172 A CA002503172 A CA 002503172A CA 2503172 A CA2503172 A CA 2503172A CA 2503172 A1 CA2503172 A1 CA 2503172A1
Authority
CA
Canada
Prior art keywords
methyl
tetrahydro
oxazocine
benz
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002503172A
Other languages
English (en)
Inventor
Andrew Douglas Baxter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sosei R&D Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0229743A external-priority patent/GB0229743D0/en
Priority claimed from GB0316914A external-priority patent/GB0316914D0/en
Application filed by Individual filed Critical Individual
Publication of CA2503172A1 publication Critical patent/CA2503172A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/22—Eight-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Noodles (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)

Abstract

L'invention concerne des composés représentés par la formule générale (1), dans laquelle un membre de W, X, Y et Z représente N ou CR4, et les autres représentent chacun CH; et R4 représente un substituant déterminé. Ces composés inhibent la recapture des mono-amines, et sont efficaces pour le traitement de la douleur, des vomissements, de la dépression, des états de stress post-traumatiques, des troubles déficitaires de l'attention, des troubles obsessionnels compulsifs, du syndrome prémenstruel, des toxicomanies et des dysfonctions sexuelles.
CA002503172A 2002-12-20 2003-12-22 Benzoxazocines et utilisation de ceux-ci comme inhibiteurs de la recapture des mono-amines Abandoned CA2503172A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0229743.0 2002-12-20
GB0229743A GB0229743D0 (en) 2002-12-20 2002-12-20 Novel benzoxazocines
GB0316914A GB0316914D0 (en) 2003-07-18 2003-07-18 Novel benzoxazocines
GB0316914.1 2003-07-18
PCT/GB2003/005708 WO2004056788A1 (fr) 2002-12-20 2003-12-22 Benzoxazocines et utilisation de ceux-ci comme inhibiteurs de la recapture des mono-amines

Publications (1)

Publication Number Publication Date
CA2503172A1 true CA2503172A1 (fr) 2004-07-08

Family

ID=32683980

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002503172A Abandoned CA2503172A1 (fr) 2002-12-20 2003-12-22 Benzoxazocines et utilisation de ceux-ci comme inhibiteurs de la recapture des mono-amines

Country Status (15)

Country Link
EP (2) EP1572672B1 (fr)
JP (1) JP2006522012A (fr)
AT (1) ATE404543T1 (fr)
AU (1) AU2003295171B2 (fr)
BR (1) BR0317467A (fr)
CA (1) CA2503172A1 (fr)
DE (1) DE60322947D1 (fr)
ES (1) ES2311749T3 (fr)
HK (1) HK1075896A1 (fr)
MX (1) MXPA05006653A (fr)
NO (1) NO20052308L (fr)
NZ (1) NZ539488A (fr)
PL (1) PL377664A1 (fr)
PT (1) PT1572672E (fr)
WO (1) WO2004056788A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20060097A (en) 2002-12-20 2008-11-28 Pfizer Products Inc., Pyrimidine derivatives for the treatment of abnormal cell growth
GB2413322A (en) * 2004-04-21 2005-10-26 Arakis Ltd Nefopam analogues
EP1740558A1 (fr) * 2004-04-21 2007-01-10 Sosei R&D Ltd. Benzoxazocines et utilisation therapeutique de celles-ci comme inhibiteurs du recaptage de la monoamine
GB0408864D0 (en) * 2004-04-21 2004-05-26 Arakis Ltd Novel benzoxazocines
GB0504960D0 (en) * 2005-03-10 2005-04-20 Arakis Ltd Benzoxazocines
GB0506835D0 (en) * 2005-04-04 2005-05-11 Arakis Ltd Therapeutic use of nefopam
GB0515703D0 (en) * 2005-07-29 2005-09-07 Arakis Ltd Therapeutic use of nefopam
GB0609793D0 (en) * 2006-05-17 2006-06-28 Arakis Ltd Racemisation and recycling process
JP5194607B2 (ja) * 2006-07-26 2013-05-08 大正製薬株式会社 ソーシャルインターラクションの低下予防・改善剤
CN105687185B (zh) 2009-12-15 2019-07-09 儿童医院 使用奈福泮化合物治疗侵袭型纤维瘤病和β-联蛋白介导的疾病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3830803A (en) * 1965-05-10 1974-08-20 Riker Laboratories Inc 5-loweralkyl-1-phenyl-1,3,4,6-tetrahydro-5h-benz(f)-2,5-oxazocines and 4-ones
US3978085A (en) * 1975-03-07 1976-08-31 Riker Laboratories, Inc. Process for benz[f]-2,5-oxazocines
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
GB1586578A (en) * 1977-08-05 1981-03-18 Riker Laboratories Inc Process for the preparation of 2-(n-(2-hydroxyyethyl)-n-lower alkylaminomethyl) benzhydrols
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use

Also Published As

Publication number Publication date
EP1572672B1 (fr) 2008-08-13
ATE404543T1 (de) 2008-08-15
EP1572672A1 (fr) 2005-09-14
EP1950206A1 (fr) 2008-07-30
MXPA05006653A (es) 2005-09-30
NZ539488A (en) 2008-03-28
JP2006522012A (ja) 2006-09-28
HK1075896A1 (en) 2005-12-30
NO20052308L (no) 2005-09-05
NO20052308D0 (no) 2005-05-11
PL377664A1 (pl) 2006-02-06
PT1572672E (pt) 2008-10-02
ES2311749T3 (es) 2009-02-16
AU2003295171A1 (en) 2004-07-14
BR0317467A (pt) 2005-11-16
WO2004056788A1 (fr) 2004-07-08
AU2003295171B2 (en) 2007-09-06
DE60322947D1 (de) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2018006795A1 (fr) Composé d'acétylène aromatique ou d'éthylène aromatique, produit intermédiaire, procédé de préparation, composition pharmaceutique et leur utilisation
CN109311889A (zh) 激活素受体样激酶抑制剂
JPWO2009060835A1 (ja) 新規ユビキリン結合性小分子
JP4982886B2 (ja) 新規なアゼチジン化合物
WO2015158206A1 (fr) Dérivé c-aryl indican et composition pharmaceutique correspondante, procédé de préparation associé et utilisations associées
KR100207876B1 (ko) 치료학적으로 유용한 2-아미노테트랄린 유도체
JP7561978B2 (ja) ベンザミド類化合物及びその使用
JP5369108B2 (ja) 受動拡散型ヌクレオシド輸送体ｅｎｔ１阻害剤
CA2503172A1 (fr) Benzoxazocines et utilisation de ceux-ci comme inhibiteurs de la recapture des mono-amines
WO2023116824A1 (fr) Composé de pyridazinone et son procédé de préparation, composition pharmaceutique et utilisation associées
KR20130031323A (ko) Ｋｖ７ 칼륨 채널 개방제로서의 피페리디닐 피리미딘 아미드
JP5465716B2 (ja) Ｎｋ１受容体アンタゴニストとしての５−［５−［２−（３，５−ビス（トリフルオロメチル）フェニル）−２−メチルプロパノイルメチルアミノ］−４−（４−フルオロ−２−メチルフェニル）］−２−ピリジニル−２−アルキル−プロリンアミド
CN110590796A (zh) 喜树碱衍生物及其制备方法和应用
TW201132645A (en) Tricyclic antibiotics
JPH057389B2 (fr)
JP2020535193A (ja) 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス
CN112759545B (zh) 3-(二甲氨基甲基)哌啶-4-醇类衍生物及其制备方法和药物用途
CA2558741A1 (fr) Benzoxazocines et utilisation therapeutique de celles-ci comme inhibiteurs du recaptage de la monoamine
WO2020171073A1 (fr) Procédé de production d'un dérivé de benzazépine et d'intermédiaire correspondant
US20060019940A1 (en) Novel benzoxazocines and their therapeutic use
HUT64759A (en) Method for producing tetrazolyl-(phenoxy-and phenoxy-alkyl-)-pyridinyl-pyridazines
CN112759546B (zh) 3-(二甲氨基甲基)哌啶-4-醇衍生物及其制备方法和药物用途
WO2021228215A1 (fr) COMPOSÉ BIARYLE CAPABLE DE SERVIR DE RÉGULATEUR DE RORγ
ZA200503509B (en) Benzoxazocines and their use as monoamine-reuptake inhibitors
WO2019196780A1 (fr) Nouvel inhibiteur de l'indoléamine 2,3-dioxygénase, son procédé de préparation et son utilisation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued